SOPHiA GENETICS

SOPHiA GENETICS Current Liabilities

The Current Liabilities of SOPHiA GENETICS (SOPH) as of Oct 21, 2026 is 33.81 M USD. In the previous year, Current Liabilities was 34.99 M USD — a change of -3.36% (lower).

Current Liabilities

33.81 MUSD

YoY

-3.36%

Last updated:

Current Liabilities of SOPHiA GENETICS is 2025 33.81 M USD. Current Liabilities of SOPHiA GENETICS was 2024 34.99 M USD. It decreases by -3.36% lower compared to the previous year.

The SOPHiA GENETICS Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
8.90 M USD
Jan 1, 2019
25.44 M USD
Jan 1, 2020
30.25 M USD
Jan 1, 2021
39.94 M USD
Jan 1, 2022
38.82 M USD
Jan 1, 2023
45.75 M USD
Jan 1, 2024
34.99 M USD
Jan 1, 2025
33.81 M USD
The SOPHiA GENETICS Current Liabilities history
YEARCurrent LiabilitiesYoY
33.81 MUSD-3.36%
34.99 MUSD-23.53%
45.75 MUSD+17.85%
38.82 MUSD-2.81%
39.94 MUSD+32.04%
30.25 MUSD+18.89%
25.44 MUSD+185.92%
8.90 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SOPHiA GENETICS Stock analysis

What does SOPHiA GENETICS do? Sophia Genetics SA is a Swiss company that was founded in 2011. The idea behind it was to improve genome sequencing and data analysis in order to make faster and more precise medical diagnoses. Sophia Genetics has since become a leading provider of artificial intelligence and data analysis in the medical field. The business model of Sophia Genetics is based on providing doctors and medical facilities with corresponding data analysis tools and platforms. Sophia Genetics' algorithms help to identify genetic anomalies and develop personalized therapies. This personalized medicine aims to improve healthcare. Sophia Genetics is divided into various sectors. The core sectors include oncology, pediatrics, cardiology, and neurology. In these specialized fields, Sophia Genetics' platforms and tools are used to optimize genome sequencing and data analysis, thus enabling faster and more precise diagnoses. The company offers a variety of products that help doctors and medical facilities create successful diagnoses and therapies. Sophia Genetics' flagship product is the Sophia Artificial Intelligence (AI) platform. This platform is used by doctors, clinics, and research institutions to analyze complex data and identify the genetic causes of diseases. The Sophia AI platform provides fast, precise, and secure genome sequencing and data analysis. Sophia Genetics also offers the Sophia DDM system. The DDM system is a cloud-based data exchange system that provides doctors and medical facilities with a secure way to exchange confidential medical data. The system also allows for the collection and analysis of information about diseases and disease progression in the population, in order to enable better healthcare. Another important product of Sophia Genetics is the Sophia Hereditary Cancer Solution. This product helps in the early detection of hereditary cancer. The Sophia Hereditary Cancer Solution provides fast and precise genetic diagnostics to identify family members at increased risk of cancer and take appropriate measures. Another product of Sophia Genetics is Sophia Radiomics. This software uses artificial intelligence and machine learning to detect and characterize diseases based on X-ray and CT scans. By analyzing large amounts of data, the Sophia Radiomics software can assist doctors in making more precise diagnoses and better treatment decisions. Sophia Genetics relies on close collaboration with medical facilities and research institutions worldwide. The company now has customers in over 60 countries and is a partner to more than 1,000 hospitals worldwide. Sophia Genetics' platforms and tools have already helped many people to be diagnosed and treated faster and more accurately. Overall, Sophia Genetics is an innovative company that has revolutionized medical diagnostics. With its advanced platforms and tools, the company provides doctors and medical facilities with an excellent opportunity to develop personalized therapies and enable better healthcare. SOPHiA GENETICS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SOPHiA GENETICS stock

Current Liabilities of SOPHiA GENETICS is 33.81 M USD in 2025.

Current Liabilities of SOPHiA GENETICS changed from 34.99 M USD to 33.81 M USD, representing a -3.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities SOPHiA GENETICS since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's SOPHiA GENETICS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — SOPHiA GENETICS

All Key Metrics — SOPHiA GENETICS